Reaction

Vena Cava Thrombosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,645 reports · 57 co-occurring drugs

As of the last recalculation, Vena Cava Thrombosis appears in 1,645 FAERS reports alongside 57 co-occurring drug terms. The strongest observed disproportionality signal is DROSPIRENONE AND ETHINYL ESTRADIOL (PRR 55.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Drospirenone And Ethinyl Estradiol	175	55.9	56.2
Bleomycin Sulfate	25	31.1	31.2
Ifosfamide	48	29.1	29.2
Mesna Injection	16	24.7	24.8
Mesna	15	22.7	22.8
Fondaparinux Sodium	13	20.5	20.5
Heparin Sodium	21	19.6	19.6
Lanreotide Acetate	11	17.9	17.9
Cisplatin	103	17.7	17.8
Etonogestrel And Ethinyl Estradiol	29	16.8	16.8
Etoposide	87	15.8	15.8
Gemcitabine	45	14.8	14.8
Gemcitabine Hydrochloride	60	14.8	14.8
Panitumumab	18	14.7	14.7
Granisetron Hydrochloride	11	13.4	13.4
Obinutuzumab	17	13.2	13.2
Granisetron	10	12.1	12.1
Alteplase	14	11.9	11.9
Fluorouracil Cream, 0.5%	68	11.7	11.7
Fluorouracil	68	11.6	11.6
Tranexamic Acid	8	11.4	11.4
Loperamide Hydrochloride Oral	9	11.2	11.2
Cefazolin	8	11.1	11.2
Aprepitant	16	11.1	11.1
Dalteparin Sodium	9	10.8	10.8
Enoxaparin Sodium	46	10.4	10.4
Cytarabine	47	10.2	10.2
Everolimus Tablets	13	9.9	9.9
Cetuximab	22	9.0	9.0
Loperamide Hcl	9	8.9	8.9
Doxorubicin	59	8.7	8.7
Teduglutide	9	8.5	8.5
Romiplostim	10	8.4	8.5
Pazopanib Hydrochloride	17	8.0	8.0
Carboplatin	76	7.9	7.9
Sunitinib Malate	23	7.5	7.5
Paclitaxel (Aibumin-Bound)	46	7.3	7.3
Trifluridine And Tipiracil	6	7.1	7.1
Oxaliplatin	40	7.0	7.0
Pemetrexed Disodium	20	6.7	6.7
Bevacizumab	63	6.7	6.7
Everolimus	26	6.6	6.6
Erlotinib	5	6.5	6.6
Pemetrexed	11	6.5	6.5
Paclitaxel	49	6.4	6.4
Cyclophosphamide Injection, Solution	84	6.3	6.3
Cyclophosphamide	84	6.3	6.3
Cyclophosphamide For Injection	84	6.3	6.3
Venetoclax	30	6.3	6.3
Aflibercept	15	6.1	6.1
Doxorubicin Hydrochloride	15	5.9	5.9
Gefitinib	4	5.6	5.6
Cabozantinib	20	5.3	5.3
Erlotinib Hydrochloride	5	5.1	5.1
Irinotecan Hydrochloride	5	4.9	4.9
Rucaparib	3	4.3	4.3
Atezolizumab	12	3.9	3.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.